VIR - long - catalyst / gap play

2月23日

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

This is not a financial advice!

2 upcoming catalyst on 30rd of June 2024 and 1 in 2H 2024 and even more EOY

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

6.57% short float

Rel. Vol. at 1.54 - it will increase in upcoming days / weeks imo

Good news has been dropped

We might see a little PB to around 11.0 where is a good entry - you could enter at 11.50 too if u want.

Keep an eye on 14.0, 16.0 and 18.0 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.

SL under 9.5

TP approx. 22.0

Most info on the chart.

Trade carefully!

2月28日

注释

February 27, 2024

VIR
Block Trade: VIR 577,500 @ $11.43


February 27, 2024
VIR
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

3月7日

注释

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule